Indegene Limited (INDGN) AI Stock Analysis

• Market Cap: ₹115.24B
• Dividend Yield: 0.38%
• Average Volume (3M): 17.62K
• Price to Earnings (P/E): 27.1
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 4,367
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 4.30
• Shares Outstanding: 240,466,750
• 10 Day Avg. Volume: 12,460
• 30 Day Avg. Volume: 17,622
• PEG Ratio: 1.56
• Price to Book (P/B): 5.26
• Price to Sales (P/S): 4.85
• P/FCF Ratio: 33.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹550.00
• Price Target Upside: 5.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): 19.01
• Revenue Forecast (FY): ₹34.45B

• Rating: 66 Neutral
• Price Target: ₹518.00 ▼(-0.81% Downside)
• Action: Downgraded Date: 10/08/25
• Date: Action: Downgraded 10/08/25

Indegene Limited's strong financial performance is the primary driver of its overall score, supported by robust revenue growth and a solid balance sheet. However, technical indicators suggest a bearish trend, and the stock appears overvalued with a high P/E ratio and low dividend yield, which weigh down the overall score.

Positive Factors

Revenue Growth & Business Model Strength

Indegene's ~18% revenue growth reflects durable demand for outsourced, tech-enabled commercialization and medical services. The firm's ability to cross-sell commercial, medical, analytics and platform services supports recurring, multi-year client programs and predictable revenue streams.

High Margins and Cost Efficiency

Sustained high gross and operating margins indicate scalable delivery, pricing power, and operational leverage from platform-led services. Margins support reinvestment in tech and talent and provide a buffer against cyclical client demand over a multi-quarter to multi-year horizon.

Strong Balance Sheet & Low Leverage

A robust equity base and low leverage give Indegene financial flexibility to fund organic growth, platform investment, or selective M&A. Strong balance sheet reduces refinancing risk and supports sustained operations through industry cycles over the coming months.

Negative Factors

Free Cash Flow Volatility

Inconsistent free cash flow growth and volatility in investing/financing cash flows weaken predictability of available capital for reinvestment or acquisitions. This intermittency can constrain strategic execution and make funding costs or timing for initiatives less certain.

Earnings / EBITDA Volatility

A sharp EBITDA drop in 2025 and variable net income point to sensitivity in margins from contract mix, pricing or cost pressures. Persistent earnings volatility could undermine long-term margin sustainability and complicate multi-period planning for investments and hiring.

Balance Sheet Fluctuations

Observed swings in liabilities and equity signal potential episodic funding, accounting, or working-capital shifts. Such instability can affect covenant headroom, borrowing flexibility, and the company's ability to smoothly finance growth initiatives over the medium term.

Indegene Limited Business Overview & Revenue Model

Company Description

Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.

How the Company Makes Money

Indegene makes money primarily through its service-based and product-based revenue models. The company's key revenue streams include providing strategic advisory services, technology platforms, and managed services to pharmaceutical companies, biotech firms, medical device manufacturers, and healthcare payers. Indegene partners with its clients to deliver customized solutions that optimize clinical development, accelerate time-to-market for new therapies, and enhance patient engagement. Additionally, strategic partnerships and collaborations with leading healthcare organizations contribute significantly to its earnings by expanding its reach and enhancing its service offerings.

Indegene Limited Financial Statement Overview

Summary

Indegene Limited demonstrates strong financial health with consistent revenue growth and profitability, supported by a solid balance sheet structure and effective cash flow management. High margins and a stable equity position are positives, though there are potential risks from cash flow volatility and net income inconsistencies.

Income Statement

Indegene Limited has demonstrated robust revenue growth over the years, with a notable increase in total revenue from 2021 to 2025. The company's EBIT and EBITDA margins have shown strong performance, reflecting efficient cost management. However, the sharp decline in EBITDA in 2025 warrants attention. The gross profit margin remains consistently high, indicating a solid business model. Net profit margin is healthy, although net income growth has varied, suggesting some volatility.

Balance Sheet

The company maintains a strong equity base, as indicated by the high stockholders' equity and a low debt-to-equity ratio in recent years, reflecting financial stability. The equity ratio is substantial, implying significant ownership of assets financed by equity. The reduction in total debt and the increase in assets over the years are positive indicators. However, fluctuations in liabilities and equity suggest some balance sheet instability that requires monitoring.

Cash Flow

Operating cash flow has remained strong, aligning well with net income, indicating good cash conversion efficiency. Free cash flow has grown, reflecting improved operational efficiency, although the growth rate in free cash flow has been inconsistent. The company has managed its capital expenditures efficiently, but the volatility in investing and financing cash flows suggests potential risks in cash flow management.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	29.24B	28.39B	25.90B	23.06B	16.65B	9.66B
Gross Profit	23.43B	7.72B	25.31B	5.81B	6.10B	9.66B
EBITDA	6.41B	5.34B	5.84B	4.54B	2.66B	2.64B
Net Income	4.35B	4.07B	3.37B	2.66B	1.65B	1.49B
Balance Sheet
Total Assets	0.00	33.26B	25.46B	22.04B	13.53B	5.96B
Cash, Cash Equivalents and Short-Term Investments	16.64B	16.64B	9.85B	7.11B	6.26B	1.33B
Total Debt	0.00	1.02B	4.90B	5.03B	657.52M	513.88M
Total Liabilities	-26.16B	7.10B	11.16B	11.40B	5.90B	2.63B
Stockholders Equity	26.16B	26.16B	14.29B	10.64B	7.64B	3.25B
Cash Flow
Free Cash Flow	0.00	4.12B	4.97B	1.11B	2.72B	1.51B
Operating Cash Flow	0.00	4.42B	5.08B	1.30B	2.97B	1.72B
Investing Cash Flow	0.00	-6.83B	-3.27B	-8.93B	-1.60B	-242.49M
Financing Cash Flow	0.00	2.88B	-662.00M	3.33B	2.33B	-1.32B

Indegene Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 522.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INDGN, the sentiment is Neutral. The current price of 522.25 is above the 20-day moving average (MA) of 486.61, above the 50-day MA of 498.84, and below the 200-day MA of 545.39, indicating a neutral trend. The MACD of -0.59 indicates Negative momentum. The RSI at 53.37 is Neutral, neither overbought nor oversold. The STOCH value of 70.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:INDGN.

Indegene Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TATAELXSI	74 Outperform	₹277.28B	48.42	―	1.38%	-1.19%	-17.92%
MPHASIS	73 Outperform	₹430.62B	24.28	―	1.94%	8.73%	11.33%
INDGN	66 Neutral	₹115.24B	27.07	―	0.38%	―	―
KPITTECH	66 Neutral	₹206.90B	29.18	―	0.69%	13.34%	5.98%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
TECHM	55 Neutral	₹1.32T	25.98	―	2.76%	3.30%	36.78%
ITI	49 Neutral	₹250.02B	-169.30	―	―	30.27%	65.87%

Indegene Limited Corporate Events

Indegene to Acquire Two UK Consulting Subsidiaries, Expands Healthcare Services Footprint

Indegene Limited’s wholly owned unit, Indegene Healthcare UK Limited, has signed a share purchase agreement to acquire 100% of DT Associates Research and Consulting Services Limited, UK, from ILSL Holdings, Inc., and Trilogy Writing and Consulting Limited, UK, from Trilogy Writing and Consulting GmbH. Following completion, both UK-based targets will become wholly owned subsidiaries of Indegene Healthcare UK Limited, consolidating Indegene’s control over these specialist consulting and writing entities and further strengthening its operating footprint in the UK healthcare services market.

The company notified the stock exchanges under Regulation 30 of the SEBI Listing Regulations and indicated that additional disclosure details are available via an annexure and on its website. The move underscores Indegene’s ongoing inorganic expansion strategy via its international subsidiaries, potentially enhancing service breadth and market positioning for stakeholders across its global healthcare and life sciences client base.

Indegene Shareholders Approve Appointment of Neeraj Bharadwaj as Independent Director via Postal Ballot

Indegene Limited has announced that its shareholders have approved, via a postal ballot conducted through remote e-voting, a special resolution appointing Mr. Neeraj Bharadwaj as an Independent Director of the company. The voting process, carried out in compliance with SEBI listing regulations and the Companies Act, reflects the company’s ongoing efforts to strengthen its board with independent oversight, a move that may enhance corporate governance standards and support strategic decision-making as Indegene continues to scale its operations in the healthcare and life sciences services market.

Indegene Consolidates Canadian Subsidiaries Into Indegene Healthcare Canada Inc.

Indegene Limited has announced the amalgamation of its two Canadian step-down subsidiaries, Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc., into a single entity named Indegene Healthcare Canada Inc., effective January 1, 2026. The internal restructuring, which is a related-party transaction with no cash consideration or change in the listed entity’s shareholding pattern, consolidates projected FY25-26 revenues of CAD 1.375 million and CAD 5.4 million from the respective businesses, streamlining Indegene’s Canadian operations and aligning its medical writing, regulatory documentation, and commercialization capabilities under one corporate structure.

Indegene Appoints Neeraj Bharadwaj as Independent Director, Allots Shares Under ESOP and RSU Plans

Indegene Limited’s board has approved the appointment of Neeraj Bharadwaj as a Non-Executive Independent Director for a five-year term starting January 25, 2026, subject to shareholder approval via postal ballot. Bharadwaj, a seasoned investment and private equity professional with degrees from the University of Pennsylvania and Harvard University, brings substantial expertise in finance, strategy, and corporate governance, which is expected to strengthen Indegene’s board oversight and strategic direction as it scales its healthcare and life sciences services business. The board also cleared the allotment of 149,635 shares under the company’s ESOP 2020 and RSU 2020 plans, signaling continued use of equity-based incentives to attract and retain key talent.